TWI825169B - 妥布賴森(tubulysins)及其中間體之製備之替代方法 - Google Patents

妥布賴森(tubulysins)及其中間體之製備之替代方法 Download PDF

Info

Publication number
TWI825169B
TWI825169B TW108132162A TW108132162A TWI825169B TW I825169 B TWI825169 B TW I825169B TW 108132162 A TW108132162 A TW 108132162A TW 108132162 A TW108132162 A TW 108132162A TW I825169 B TWI825169 B TW I825169B
Authority
TW
Taiwan
Prior art keywords
optionally substituted
moiety
group
formula
compound
Prior art date
Application number
TW108132162A
Other languages
English (en)
Chinese (zh)
Other versions
TW202024043A (zh
Inventor
吳坤亮
慶武 金
文戴爾 道博戴
Original Assignee
美商思進公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商思進公司 filed Critical 美商思進公司
Publication of TW202024043A publication Critical patent/TW202024043A/zh
Application granted granted Critical
Publication of TWI825169B publication Critical patent/TWI825169B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TW108132162A 2018-09-07 2019-09-06 妥布賴森(tubulysins)及其中間體之製備之替代方法 TWI825169B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862728639P 2018-09-07 2018-09-07
US62/728,639 2018-09-07

Publications (2)

Publication Number Publication Date
TW202024043A TW202024043A (zh) 2020-07-01
TWI825169B true TWI825169B (zh) 2023-12-11

Family

ID=68000124

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108132162A TWI825169B (zh) 2018-09-07 2019-09-06 妥布賴森(tubulysins)及其中間體之製備之替代方法

Country Status (17)

Country Link
US (1) US20230002440A1 (https=)
EP (1) EP3847161A1 (https=)
JP (1) JP7511543B2 (https=)
KR (1) KR20210073525A (https=)
CN (1) CN112996778A (https=)
AU (1) AU2019336231A1 (https=)
BR (1) BR112021004317A2 (https=)
CA (1) CA3111149A1 (https=)
EA (1) EA202190699A1 (https=)
IL (1) IL281090A (https=)
MA (1) MA53550A (https=)
MX (1) MX2021002570A (https=)
SA (1) SA521421375B1 (https=)
SG (1) SG11202102126VA (https=)
TW (1) TWI825169B (https=)
UA (1) UA128730C2 (https=)
WO (1) WO2020051503A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115867283A (zh) * 2020-12-23 2023-03-28 启德医药科技（苏州）有限公司 包含开环硫代琥珀酰亚胺基团、寡肽片段和手性部分的新型异构化合物
BR112023018676A2 (pt) 2021-03-18 2023-10-10 Seagen Inc Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008138561A1 (en) * 2007-05-10 2008-11-20 R & D Biopharmaceuticals Gmbh Tubulysine derivatives
IT1394860B1 (it) 2009-07-22 2012-07-20 Kemotech S R L Composti farmaceutici
KR20180090290A (ko) 2015-12-04 2018-08-10 시애틀 지네틱스, 인크. 사차화 튜불리신 화합물들의 컨쥬게이트들
KR20200051733A (ko) * 2017-09-08 2020-05-13 시애틀 지네틱스, 인크. 튜불리신 및 그 중간물의 제조 공정

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 MONICA SANI ET AL "Studies towards a Novel Synthesis of Tubulysins: Highly Asymmetric Aza-Michael Reactions of 2-Enoylthiazoles with Metalated Chiral Oxazolidinones" SYNLETT, vol. 2009, no. 08, 17 April 2009 pages 1341-1345。

Also Published As

Publication number Publication date
JP2021536475A (ja) 2021-12-27
JP7511543B2 (ja) 2024-07-05
IL281090A (en) 2021-04-29
MA53550A (fr) 2021-12-15
UA128730C2 (uk) 2024-10-09
WO2020051503A1 (en) 2020-03-12
TW202024043A (zh) 2020-07-01
CA3111149A1 (en) 2020-03-12
BR112021004317A2 (pt) 2021-05-25
CN112996778A (zh) 2021-06-18
SG11202102126VA (en) 2021-04-29
EA202190699A1 (ru) 2021-06-08
EP3847161A1 (en) 2021-07-14
US20230002440A1 (en) 2023-01-05
MX2021002570A (es) 2021-06-08
AU2019336231A1 (en) 2021-03-18
SA521421375B1 (ar) 2024-02-11
KR20210073525A (ko) 2021-06-18

Similar Documents

Publication Publication Date Title
JP2023106627A (ja) Ｐｅｇ化薬物リンカー及びその中間体を調製するためのプロセス
TW202114739A (zh) 含三級胺之藥物之標的遞送
KR20230133312A (ko) 캄프토테신 항체-약물 접합체 및 이의 사용 방법
TWI838358B (zh) 疏水性奧瑞他汀(auristatin)f化合物及其結合物
JP2022518743A (ja) 抗体－薬物コンジュゲート用のグリコシド含有ペプチドリンカー
EP4306535A1 (en) Compound or salt thereof, and antibody obtained using same
JP2023053386A (ja) チューブリシンおよびそれらの中間体の調製のためのプロセス
TWI825169B (zh) 妥布賴森(tubulysins)及其中間體之製備之替代方法
CA3208290A1 (en) Compound or salt thereof, and antibody obtained by using the same
HK40045709A (en) Alternative processes for the preparation of tubulysins and intermediates thereof
HK40036588A (en) Process for the preparation of tubulysins and intermediates thereof
HK40009733A (en) Process for the preparation of pegylated drug-linkers and intermediates thereof